Research Interest:
Hematological malignancies and bone marrow transplantation
Positions: Medical Director, Clinical Trials Office, Hollings Cancer Center, Medical University of South Carolina Co-Director, Hematological Malignancies Program , Medical University of South Carolina Director, Blood and Marrow Transplantation (BMT) Program, Medical University of South Carolina
Selected Publications:
| 1. | Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. .89(5):432-4, 2012.
View in: PubMed
| | 2. | Abbas JA, Stuart RK. Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs. .21(8):1223-33, 2012.
View in: PubMed
| | 3. | Butler C, Wolff DJ, Kang Y, Stuart RK, Costa LJ. Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leuk Lymphoma. .53(12):2444-8, 2012.
View in: PubMed
| | 4. | Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. .30(20):2492-9, 2012.
View in: PubMed
| | 5. | Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. .47(11):1403-8, 2012.
View in: PubMed
| | 6. | Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. .52(11):2375-81, 2012.
View in: PubMed
| | 7. | Rivell GL, Brunson CY, Milligan L, Stuart RK, Costa LJ. Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol. .86(8):699-701, 2011.
View in: PubMed
| | 8. | Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart R, Perrotti D, Ogretmen B. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. .117(22):5941-52, 2011. PMCID: PMC3112039
View in: PubMed
| | 9. | Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res. .17(10):3388-97, 2011. PMCID: PMC3096752
View in: PubMed
| | 10. | Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Transfusion. .51(9):1995-2000, 2011.
View in: PubMed
| | 11. | Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. .117(12):3294-301, 2011. PMCID: PMC3069671
View in: PubMed
| | 12. | Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. .17(5):1140-6, 2011. PMCID: PMC3049960
View in: PubMed
| | 13. | Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. .17(8):1176-81, 2010.
View in: PubMed
| | 14. | Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. .151(5):430-4, 2010. PMCID: PMC3058291
View in: PubMed
| | 15. | Adams B, Lazarchick J, Medina AM, Willner IR, Neville B, Murphy E, Stuart R, Costa LJ. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. .85(8):627-9, 2010.
View in: PubMed
| | 16. | Toms DR, Cannick L, Stuart RK, Jenrette JM, Terwiliger L. Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia. Jpn J Radiol. .28(6):476-8, 2010.
View in: PubMed
| | 17. | Costa LJ, Moussa O, Bray RA, Stuart RK. Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure. Br J Haematol. .151(1):94-6, 2010.
View in: PubMed
| | 18. | Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant. .46(4):523-8, 2010.
View in: PubMed
| | 19. | Post GR, Holloman D, Christiansen L, Smith J, Stuart R, Lazarchick J. Translocation t(3;8;9)(p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: a unique case and review of the literature. Leuk Res. .34(11):1543-4, 2010.
View in: PubMed
| | 20. | Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. .46(1):64-9, 2010.
View in: PubMed
| | 21. | Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. .19(3):427-36, 2010.
View in: PubMed
| | 22. | Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. .28(5):815-21, 2009.
View in: PubMed
| | 23. | Holloman D, Eberts P, Clark C, Lewin D, Lazarchick J, Stuart R, Comerford L. Extensive involvement of the gastrointestinal tract by a de novo presentation of the monoblastic type of myeloid sarcoma: a case report of a rare entity that is often misdiagnosed. Am J Med Sci. .338(6):513-6, 2009.
View in: PubMed
| | 24. | Shirai K, Sera Y, Bulkeley W, Mehrotra M, Moussa O, LaRue AC, Watson DK, Stuart RK, Lazarchick J, Ogawa M. Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. .37(12):1464-71, 2009. PMCID: PMC2802494
View in: PubMed
| | 25. | Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. .114(19):4027-33, 2009.
View in: PubMed
| | 26. | Gattoni-Celli S, Buckner CL, Lazarchick J, Stuart RK, Fernandes DJ. Overexpression of nucleolin in engrafted acute myelogenous leukemia cells. Am J Hematol. .84(8):535-8, 2009.
View in: PubMed
| | 27. | Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma AK. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. .31(4):493-502, 2009.
View in: PubMed
| | 28. | Vu KN, Day TA, Gillespie MB, Martin-Harris B, Sinha D, Stuart RK, Sharma AK. Proximal esophageal stenosis in head and neck cancer patients after total laryngectomy and radiation. ORL J Otorhinolaryngol Relat Spec. .70(4):229-35, 2008.
View in: PubMed
| | 29. | Znoyko I, Stuart RK, Ellingham T, Winters J, Wolff DJ, Quigley DI. Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report. Cancer Genet Cytogenet. .183(1):64-8, 2008.
View in: PubMed
| | 30. | Amria S, Cameron C, Stuart R, Haque A. Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk Lymphoma. .49(2):353-5, 2008.
View in: PubMed
| | 31. | Watkins JM, Stuart RK, Davis BK, Day TA, Chaudharry UB, Sharma AK. Long-term survival following salvage reirradiation with concurrent chemotherapy for recurrent head and neck cancer. J S C Med Assoc. .104(2):36-9, 2008.
View in: PubMed
| | 32. | Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, Stuart RK, Spicer EK, Fernandes DJ. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. .109(7):3069-75, 2007. PMCID: PMC1852223
View in: PubMed
| | 33. | Bilic M, Quigley DI, Stuart RK, Wolff DJ. Jumping translocation of 1q in BCR/ABL-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet. .172(1):90-1, 2007.
View in: PubMed
| | 34. | Day TA, Deveikis J, Gillespie MB, Joe JK, Ogretmen B, Osguthorpe JD, Reed SG, Richardson MS, Rossi M, Saini R, Sharma AK, Stuart RK. Salivary gland neoplasms. Curr Treat Options Oncol. .5(1):11-26, 2004.
View in: PubMed
| | 35. | Onitilo AA, Lazarchick J, Brunson CY, Frei-Lahr D, Stuart RK. Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. .35(8):3089-92, 2003.
View in: PubMed
| | 36. | Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, Neville B, Richardson MS, Rosenzweig S, Sharma AK, Smith MM, Stewart S, Stuart RK. Oral cancer treatment. Curr Treat Options Oncol. .4(1):27-41, 2003.
View in: PubMed
| | 37. | Frankel AE, Baer MR, Hogge DE, Stuart RK. Immunotherapy of acute myeloid leukemia. Curr Pharm Biotechnol. .2(3):209-15, 2001.
View in: PubMed
| | 38. | Ezzat AA, Ibrahim EM, El Weshi AN, Khafaga YM, AlJurf M, Martin JM, Ajarim DS, Bazarbashi SN, Stuart RK, Zucca E. Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck. .23(7):547-58, 2001.
View in: PubMed
| | 39. | Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Stuart RK, Tulbah AM, Kandil A, Al-Malik OA, Bazarbashi SM. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat. .62(3):237-44, 2000.
View in: PubMed
| | 40. | Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant. .26(1):1-16, 2000.
View in: PubMed
| | 41. | Ezzat AA, Ibrahim EM, Stuart RK, Ajarim D, Bazarbashi S, El-Foudeh MO, Rahal M, Al-Sayed A, Berry J. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. .17(1):39-46, 2000.
View in: PubMed
| | 42. | Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. .18(1):148-57, 2000.
View in: PubMed
| | 43. | Ibrahim EM, Ezzat AA, Raja MA, Rahal MM, Ajarim DS, Mann B, Baloush A, Stuart RK, Bazarbashi SN. Primary gastric non-Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Ann Oncol. .10(12):1441-9, 1999.
View in: PubMed
| | 44. | Gospodarowicz M. Individuality versus conformity. Is perfection necessary in staging and prognostic classifications of specific primary extranodal lymphomas? Ann Oncol. .10(12):1405-7, 1999.
View in: PubMed
| | 45. | Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. .5(7):1723-30, 1999.
View in: PubMed
| | 46. | Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK. Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol. .16(2):95-103, 1999.
View in: PubMed
| | 47. | Ibrahim EM, al-Mulhim FA, al-Amri A, al-Muhanna FA, Ezzat AA, Stuart RK, Ajarim D. Breast cancer in the eastern province of Saudi Arabia. Med Oncol. .15(4):241-7, 1998.
View in: PubMed
| | 48. | Rogers RL, Javed TA, Ross RE, Virella G, Stuart RK, Frei-Lahr D. Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation. Am J Hematol. .57(4):326-30, 1998.
View in: PubMed
| | 49. | Stuart RK. Autologous bone marrow transplantation for leukemia. Semin Oncol. .20(5 Suppl 6):40-54, 1993.
View in: PubMed
| | 50. | Daley BJ, Maliakkal RJ, Dreesen EB, Champagne C, Ellison M, Thibault SA, Forse RA, Bistrian BR. Reducing arrhythmias associated with central-venous catheter insertion or exchange. Nutrition. .8(4):282, 1992.
View in: PubMed
| | 51. | Stuart RK, Baxter JK, Shikora SA, Akerman P, Apovian C, Champagne C, Jennings A, Bistrian BR. Reducing arrhythmias associated with central venous catheter insertion or exchange. Nutrition. .8(1):19-21, 1992.
View in: PubMed
| | 52. | Ross RE, Jeter EK, Stuart RK, Self SE, Lavia MF. CD34+ and CD33+ stem cells: predictors of hematologic recovery? Prog Clin Biol Res. .377:505-12, 1992.
View in: PubMed
| | 53. | Priest DG, Schmitz JC, Bunni MA, Stuart RK. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst. .83(24):1806-12, 1991.
View in: PubMed
| | 54. | Sahovic EA, Flick J, Graham CD, Stuart RK. Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. .302(6):369-73, 1991.
View in: PubMed
| | 55. | Peters RH, Jollow DJ, Stuart RK. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Cancer Res. .51(10):2536-41, 1991.
View in: PubMed
| | 56. | Stuart RK, Apovian C, Bell SJ, Blackburn GL. Perioperative nutrition in cancer patients. Nutrition. .6(4 Suppl):4S-6S, 1990.
View in: PubMed
| | 57. | White DR, Powell BL, Craig JB, Stuart RK, Schnell FM, Goldklang GA, Atkins JN, Jackson DV, Richards F, Muss HB, et al. A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study. Cancer. .65(8):1700-3, 1990.
View in: PubMed
| | 58. | Peters RH, Stuart RK. Synergism between 4-hydroperoxycyclophosphamide and cisplatin: importance of incubation sequence and measurement of cisplatin accumulation. Biochem Pharmacol. .39(3):607-9, 1990.
View in: PubMed
| | 59. | Peters RH, Ballard K, Oatis JE, Jollow DJ, Stuart RK. Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol. .26(6):397-402, 1990.
View in: PubMed
| | 60. | Peters RH, Brandon CS, Avila LA, Gale GR, Stuart RK. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Prog Clin Biol Res. .333:57-68, 1990.
View in: PubMed
| | 61. | Stuart RK. Breast cancer. Trans Assoc Life Insur Med Dir Am. .72:134-43, 1989.
View in: PubMed
| | 62. | Peters RH, Brandon CS, Avila LA, Colvin OM, Stuart RK. In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. Cancer Chemother Pharmacol. .23(3):129-34, 1989.
View in: PubMed
| | 63. | Spivak JL, Hogans BB, Stuart RK. Tumor-promoting phorbol esters support the in vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest. .83(1):100-7, 1989. PMCID: PMC303649
View in: PubMed
| | 64. | Garvin AJ, Self S, Sahovic EA, Stuart RK, Marchalonis JJ. The occurrence of a peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Am J Surg Pathol. .12(1):64-70, 1988.
View in: PubMed
| | 65. | Sieber F, Stuart RK, Rowley SD, Sharkis SJ, Sensenbrenner LL. Dye-mediated photolysis of normal and neoplastic hematopoietic cells. Leuk Res. .11(1):43-9, 1987.
View in: PubMed
| | 66. | Strauss LC, Rowley SD, La Russa VF, Sharkis SJ, Stuart RK, Civin CI. Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol. .14(9):878-86, 1986.
View in: PubMed
| | 67. | Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. .315(3):141-7, 1986.
View in: PubMed
| | 68. | Stuart RK, Mangan KF. Hematologic and cytogenetic remission of 5q-refractory anemia after syngeneic bone marrow transplantation. Am J Med. .80(3):503-7, 1986.
View in: PubMed
| | 69. | Kaizer H, Stuart RK, Brookmeyer R, Beschorner WE, Braine HG, Burns WH, Fuller DJ, Korbling M, Mangan KF, Saral R, et al. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood. .65(6):1504-10, 1985.
View in: PubMed
| | 70. | Rowley SD, Colvin OM, Stuart RK. Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide. Exp Hematol. .13(4):295-8, 1985.
View in: PubMed
| | 71. | Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Energy requirements of parenterally fed bone marrow transplant recipients. JPEN J Parenter Enteral Nutr. .9(2):139-43, 1985.
View in: PubMed
| | 72. | Strauss LC, Stuart RK, Civin CI. Antigenic analysis of hematopoiesis. I. Expression of the My-1 granulocyte surface antigen on human marrow cells and leukemic cell lines. Blood. .61(6):1222-31, 1983.
View in: PubMed
| | 73. | Wingard JR, Hess AD, Stuart RK, Saral R, Burns WH. Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation. Antimicrob Agents Chemother. .23(4):593-7, 1983. PMCID: PMC184707
View in: PubMed
| | 74. | Stuart RK, Pollack M. Pseudomonas aeruginosa exotoxin A inhibits proliferation of human bone marrow progenitor cells in vitro. Infect Immun. .38(1):206-11, 1982. PMCID: PMC347720
View in: PubMed
| | 75. | Delaney WE, Nickoloff E, Ettinger DS, Drew HM, Szeluga DJ, Stuart RK. Abnormal fatty acid breath tests in cancer patients, with nutritional correlation. Cancer. .50(4):727-31, 1982.
View in: PubMed
| | 76. | Braine HG, Stuart RK, Saral R, Lietman PS. Parenteral trimethoprim-sulfamethoxazole and carbenicillin as empiric therapy for neutropenic patients with cancer. Rev Infect Dis. .4(2):586-92, 1982.
View in: PubMed
| | 77. | Delaney WE, Stuart RK, Ettinger DS. Fatty acid breath test values in the malabsorption range in cancer patients. Nutr Cancer. .3(3):122-8, 1982.
View in: PubMed
| | 78. | Wingard JR, Stuart RK, Saral R, Burns WH. Activity of trifluorothymidine against cytomegalovirus. Antimicrob Agents Chemother. .20(3):286-90, 1981. PMCID: PMC181689
View in: PubMed
| | 79. | Sieber F, Stuart RK, Spivak JL. Tumor-promoting phorbol esters stimulate myelopoiesis and suppress erythropoiesis in cultures of mouse bone marrow cells. Proc Natl Acad Sci U S A. .78(7):4402-6, 1981. PMCID: PMC319798
View in: PubMed
| | 80. | Stuart RK, Hamilton JA, Sensenbrenner LL, Moore MA. Regulation of myelopoiesis in vitro: partial replacement of colony-stimulating factors by tumor-promoting phorbol esters. Blood. .57(6):1032-42, 1981.
View in: PubMed
|
|